Novo Nordisk woes prompt Denmark to slash country’s 2025 growth forecast

Denmark has significantly cut its 2025 economic growth forecast from 3% to 1.4%, citing weaker prospects for pharmaceutical giant Novo Nordisk due to increased competition in the weight loss drug market and the dampening effect of U.S. tariffs on Danish exports. This downgrade underscores the nation's economic sensitivity to the performance of key companies and global trade dynamics, despite an anticipated rebound in 2026 driven by higher private and public spending.

Analysis

Denmark's economy ministry has sharply revised its 2025 GDP growth forecast downward from 3.0% to 1.4%, signaling significant headwinds for the nation's economy. The downgrade is primarily attributed to two factors: the deteriorating outlook for pharmaceutical giant Novo Nordisk and the adverse impact of U.S. tariffs. Novo Nordisk, which accounted for one-fifth of the country's employment growth last year, is facing intense competition in the weight-loss drug market from U.S. rival Eli Lilly. This pressure is evidenced by Novo Nordisk's decision to cut its full-year sales and profit forecasts twice this year and now faces potential layoffs. The second driver is a slowdown in trade, with the 2025 export growth forecast slashed from 4.3% to just 0.9% due to U.S. tariffs and a significant decline in exports to the U.S. in the first half of the year. While the near-term outlook is cautious, the ministry has raised its 2026 GDP forecast to 2.1% from 1.4%, anticipating a rebound driven by higher domestic spending.

Key Decisions for Investors

• Investors in Novo Nordisk (NVO) should recognize the heightened risk from intensifying competition, as evidenced by two consecutive guidance cuts and its direct citation as a drag on Denmark's national GDP.
• The challenges detailed for Novo Nordisk implicitly strengthen the competitive position of Eli Lilly (LLY) in the lucrative obesity drug market, potentially justifying a more favorable view of LLY.
• Holders of Danish equities or currency should be cautious of near-term volatility, given the economy's high concentration risk tied to Novo Nordisk's performance and its sensitivity to U.S. trade policy.
• Monitor future Danish export data and Novo Nordisk's quarterly earnings closely for signs of stabilization, as the government's upgraded 2026 GDP forecast suggests a potential recovery path beyond the immediate headwinds.